Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | YES1 | P07947 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | BLK | P51451 | 3/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14304344 | 0.92 | BTK (0.54) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL2498477 | 0.90 | BTK (0.46) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL2498581 | 0.89 | BTK (0.47) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL2497569 | 0.85 | BTK (0.54) | BTKPDGFRBLCK | |
| SCHEMBL2495433 | 0.84 | BTK (0.47) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL12190172 | 0.84 | BTK (0.45) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL2497204 | 0.83 | BTK (0.46) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL12212900 | 0.83 | BTK (0.43) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL12190173 | 0.83 | BTK (0.46) | BTKSRCABL1YES1PDGFRB | |
| SCHEMBL2497186 | 0.83 | BTK (0.68) | BTKSRCABL1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | BTK 44/4885SRC 5/4885ABL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.